Please assess the completion status of the following clinical trial:

Trial Title: Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~Primary Phase:~* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.~* healthy male or female subject between, and including, 6 and 12 weeks of age at the time of the first vaccination, born after a gestation period between and including 36 and 42 weeks.~* Written informed consent obtained from the parent or guardian of the subject prior to the study entry.~* Free of obvious health problems as established by medical history and clinical examination before entering into the study.~Booster Phase:~• Participation in primary phase of study.~Exclusion Criteria~Primary Phase:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) since birth or planned use during the study period.~* Chronic administration (defined as more than 14 days) of immunosuppressant or other immune-modifying drugs since birth.~* Planned administration/ administration of a vaccine not foreseen by the study protocol since birth, with exception of BCG.~* Previous vaccination against meningococcal serogroup C disease, diphtheria, tetanus, pertussis, polio, pneumococcal, Hepatitis B or Hib disease~* History of Haemophilus influenzae type b and /or meningococcal serogroup C disease.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus infection.~* A family history of congenital or hereditary immunodeficiency.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* Major congenital defects or serious chronic illness.~* History of any neurologic disorders or seizures.~* Acute disease at the time of enrolment.~* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.~Additional Exclusion criteria for the Booster Phase:~• Previous booster vaccination with Hib and/or MenC and/or DTP containing and/or IPV containing and/or HepB containing vaccine(s).

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- Group Hib-MenC (Type: EXPERIMENTAL): Subjects receive 2 primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age of Hib-MenC + Infanrix™ penta vaccines.
- Group NeisVac-C (Type: ACTIVE_COMPARATOR): Subjects receive 2 primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age of NeisVac-C™ + Infanrix™ hexa vaccines.

Based on this trial design, predict the completion outcome and termination type (if applicable).